<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964196</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0303</org_study_id>
    <nct_id>NCT01964196</nct_id>
  </id_info>
  <brief_title>ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-</brief_title>
  <official_title>ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, Parallel Groups, Placebo-controlled, Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and the dose-response of ASP1517 in the treatment of&#xD;
      anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is applied&#xD;
      intermittently.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and the dose-response of ASP1517 on Hemoglobin (Hb) correction in the&#xD;
      treatment of anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is&#xD;
      applied intermittently. Patients will receive ASP1517 three times a week (TIW) for first&#xD;
      6weeks. Patients may have the second-randomization to TIW dosing or once-a-week (QW) dosing&#xD;
      at Week 6, 8, 10, 12, 14 or 16 if patients meet the criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2013</start_date>
  <completion_date type="Actual">December 1, 2015</completion_date>
  <primary_completion_date type="Actual">July 6, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of rise in Hb (g/dL/week) at Week 6</measure>
    <time_frame>Baseline and at 6 weeks after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of cumulative number of responder patients</measure>
    <time_frame>for 28 weeks after dosing</time_frame>
    <description>responder is defined as a Hb ≥10.0 g/dL and an increase in Hb by ≥1.0 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of visits at which patients maintain Hb between 10.0-12.0 g/dL after achieving Hb ≥10.0 g/dL for each patients</measure>
    <time_frame>for 28 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who maintain Hb between 10.0-12.0 g/dL at each visit</measure>
    <time_frame>Before and Week-2, -3, -4, -6, -8, -10, -12, -14, -16, -18, -20, -22, -24 and -28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hb</measure>
    <time_frame>Before and Week-2, -3, -4, -6, -8, -10, -12, -14, -16, -18, -20, -22, -24 and -28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed as the incidence of adverse events, vital signs, 12-lead ECGs and lab-tests</measure>
    <time_frame>for 28 weeks after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Anemia in Chronic Kidney Disease Patients Not on Dialysis</condition>
  <arm_group>
    <arm_group_label>ASP1517 low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1517 middle dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1517 high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1517</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>ASP1517 high dose group</arm_group_label>
    <arm_group_label>ASP1517 low dose group</arm_group_label>
    <arm_group_label>ASP1517 middle dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease with an estimated glomerular filtration rate (as calculated by&#xD;
             the Japanese GFR estimation equation) of =&lt;89 mL/min/1.73 m2, and not required&#xD;
             dialysis for 3 months since study completion&#xD;
&#xD;
          -  The mean of two Hb values at screening test and Hb test (at least one week apart form&#xD;
             the screening test) is &lt;10.0 g/dL, with a difference of ≤1.0 g/dL between the two&#xD;
             values&#xD;
&#xD;
          -  Both TSAT&gt;=5% and ferritin &gt;=30 ng/mL at screening test&#xD;
&#xD;
          -  Serum folate ≥4.0 ng/mL and Vitamin B12 ≥180 pg/mL at screening test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Proliferative retinopathy, age-related macular degeneration, retinal vein occlusion&#xD;
             and/or macular edema that is considered to require treatment&#xD;
&#xD;
          -  Immunological disease with severe inflammation as assessed by the Investigator; even&#xD;
             if the inflammation is in remission, the subject is excluded (e.g. lupus&#xD;
             erythematosus, rheumatoid arthritis, Sjogren's syndrome, celiac disease, etc).&#xD;
&#xD;
          -  Having a history of gastric/intestinal resection considered influential on the&#xD;
             absorption of the drug in the gastrointestinal tract or evidence of active&#xD;
             gastroparesis.&#xD;
&#xD;
          -  Uncontrollable hypertension (more than one third blood pressure values of diastolic BP&#xD;
             &gt;100 mmHg within 16 weeks prior to screening test including)&#xD;
&#xD;
          -  Congestive heart failure (NYHA classification III or higher)&#xD;
&#xD;
          -  Having a history of hospitalization for stroke, myocardial infarction or lung&#xD;
             infarction within 24 weeks before screening test&#xD;
&#xD;
          -  Positive for any of the following: anti-hepatitis C virus antibody (anti-HCV Ab);&#xD;
             hepatitis B surface antigen (HBsAg); or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Anemia other than anemia due to low/absent renal production of EPO (e.g., iron&#xD;
             deficiency anemia, hemolytic anemia, pancytopenia, etc)&#xD;
&#xD;
          -  Using ESA, anabolic androgenic steroid, testosterone enanthate or mepitiostane within&#xD;
             6 weeks before screening test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=397</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Renal Failure</keyword>
  <keyword>Renal anemia</keyword>
  <keyword>ASP1517</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

